Review

Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives

Vanathi Perumal 1,2,3,4, Tammy Corica 2, Arun M. Dharmarajan 1,3,4, Zhonghua Sun 5, Satvinder S. Dhaliwal 6, Crispin R. Dass 1,4 and Joshua Dass 2,*

1 School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA 6102, Australia; vanathi.perumal@curtin.edu.au (V.P); a.dharmarajan@curtin.edu.au (A.M.D); crispin.dass@curtin.edu.au (C.R.D.)
2 Radiation Oncology, Sir Charles Gairdner Hospital, Cancer Centre, Nedlands, Perth, WA 6009, Australia; Tammy.Corica@health.wa.gov.au
3 Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia
4 Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia
5 Discipline of Medical Radiation Sciences, School of Molecular and Life Sciences, Faculty of Science and Engineering, Curtin University, Perth, WA 6102, Australia; Z.Sun@exchange.curtin.edu.au
6 School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia; S.Dhaliwal@curtin.edu.au
* Correspondence: joshua.dass@health.wa.gov.au

Received: 13 February 2019; Accepted: 11 March 2019; Published: 15 March 2019

Abstract: Head and neck cancer is the seventh most common cancer in Australia and globally. Despite the current improved treatment modalities, there is still up to 50–60% local regional recurrence and or distant metastasis. High-resolution medical imaging technologies such as PET/CT and MRI do not currently detect the early spread of tumour cells, thus limiting the potential for effective minimal residual detection and early diagnosis. Circulating tumour cells (CTCs) are a rare subset of cells that escape from the primary tumour and enter into the bloodstream to form metastatic deposits or even re-establish themselves in the primary site of the cancer. These cells are more aggressive and accumulate gene alterations by somatic mutations that are the same or even greater than the primary tumour because of additional features acquired in the circulation. The potential application of CTC in clinical use is to acquire a liquid biopsy, by taking a reliable minimally invasive venous blood sample, for cell genotyping during radiotherapy treatment to monitor the decline in CTC detectability, and mutational changes in response to radiation resistance and radiation sensitivity. Currently, very little has been published on radiation therapy, CTC, and circulating cancer stem cells (CCSCs). The prognostic value of CTC in cancer management and personalised medicine for head and neck cancer radiotherapy patients requires a deeper understanding at the cellular level, along with other advanced technologies. With this goal, this review summarises the current research of head and neck cancer CTC, CCSC and the molecular targets for personalised radiotherapy response.

Keywords: circulating tumour cells; circulating cancer stem cells; radiotherapy; ctDNA; cf DNA

1. Introduction

The worldwide incidence of head and neck cancer is more than 600,000 cases with 350,000 deaths each year [1]. In Australia, it is expected to rise to about 5061 new cases in 2018, including 3725 males and 1336 females, compared to 4409 cases in 2013 [2,3]. Some of the associated confounding factors include tobacco-chewing, smoking, alcoholism, poor oral hygiene and p16 (cyclin-dependent kinase inhibitor 2A, multiple tumour suppressor 1) status in oral cancers. Typically, there are five main types
of head and neck cancer: laryngeal and hypopharyngeal (voice box), nasal cavity and paranasal sinus (behind the nose), nasopharyngeal in the upper part of the throat (behind the nose), oral and oropharyngeal (mouth, tongue and salivary glands) [4–10]. These tumours predominantly originate from the squamous cells lining the surfaces of mouth, nose and the throat. The majority of head and neck cancers are squamous cell carcinomas (HNSCC). Despite recent improvements in loco-regional control, 50–60% of HNSCCs develop loco-regional recurrence, a further 20% progressing to distant metastasis and therefore treatment failure [11]. Hence, globally the diagnosis and prognosis of HNSCC remains a challenge [12].

These statistics indicate that there is an immediate need for improved therapy modalities specifically for the HNSCC patients who are at the risk of loco regional or distant metastasis. In clinical practice, it may be difficult to obtain tumour tissue from patients for gene alteration discoveries to tailor treatment. Currently, radiotherapy alone or in combination with chemo-radiotherapy has been reasonably effective for HNSCC but there is room for improvement [13–15]. Hence, the combined effort of researchers and clinical investigators will expand the horizons in discovering new effective biomarkers for clinical utility [16,17].

Despite the emergence of recent state-of-the-art radiotherapy modalities such as Image-Guided Radiation Therapy (IGRT), Intensity-Modulated Radiation Therapy (IMRT), Volumetric Modulated Radiation Therapy (VMRT) or Stereotactic Ablative Body Radiotherapy (SABR), there is a limitation on the precise dose delivery associated with tumour volume and on the biological effect [18] in determining the radioresistance and sensitivity index of the patient. Radioresistance and radiosensitivity may vary depending on the cell type and origin and the genetic makeup of the patient. Cancer stem cells (CSCs) are more resistant to radiotherapy [19,20]. Failure in repairing the double strand breaks of DNA by radiotherapy accumulates mutation, causing genomic instability [21,22]. Currently, radiation oncology is being revolutionised into a new era with more precise and exciting radiobiological advancement technologies by using CTCs and CCSCs. Ionising radiation to the primary tumour target can affect the non-primary tumours favourably or unfavourably, which is termed an “abscopal” effect. From an oncologist’s point of view, reduction in the tumour size is the measured criteria, whereas from a biologist’s point of view, the measured criterion is the epigenetic modification causing tumorigenic alteration and cell death in healthy tissues. The use of high-dose radiotherapy fractionation in combination with appropriately improved systemic agents will be more beneficial in controlling the tumour burden and in protecting healthy tissues from local recurrence [23]. Thus, the rationale for identifying active cancer by investigating the presence of CTCs is not only a diagnostic tool but will also serve as a proof of concept in guiding the efficacy of current clinical radiotherapy treatment modalities [24].

2. CTC Origin and Methodologies

In 1869, the Australian physician Thomas Ashworth [25] discovered the existence of CTCs in blood during the autopsy of a metastatic cancer patient. Later on, in 1889, Paget [26] postulated the “seed and soil theory” based on his observations in metastatic breast cancer. Now CTC isolation and detection have progressed into a new era. Currently, there are different approaches available for the identification of CTCs based on the physical properties, expression of biomarkers or functional characteristics of the tumour [27,28].

Solid tumour CTC isolation is commonly based on the biological properties which are enriched either by EpCAM (epithelial cell adhesion molecule) positive selection or CD2, CD14, CD16, CD19, CD45, CD61, CD66b and Glycophorin A negative selection of cell surface antibodies (such as Stem Cell Technologies Human CTC Enrichment Kit, Rosette sep product CTC kit, MACS cell separation-Miltenyl Biotec Immunomagnetic bead kit) [3,29–32]. CTC isolation can also be enriched by ficoll density gradient, deformability or electric charges dielectrophoresis (DEP), flow cytometry, immuno-microbubbles and protein epithelial immunospot (EPISPOT) methods. The other microfluidic platform system (CTC-chip) [32] and isolation via size of epithelial tumour cells (ISET) filtration
methodologies are based on the size of the CTC specific to tumour type. For further precise validation and to avoid false negative findings, immunostaining or reverse transcription PCR (RT-PCR) methods can be supported by a genomic approach using fluorescent in situ hybridisation (FISH) or single cell analysis. Among various CTC methodologies, CellSearch® System (Veridex, Huntington Valley, PA 19006, USA) CTC test is the only method that has been approved by the FDA (Food and Drug Administration) such that it can be used as a surrogate marker of overall and progression-free survival for only few types of cancer like breast, prostate and colorectal cancers [33]. In a comparative study of CTC methodology on breast cancer, Kallergi et al. [34] reported ISET platform performance for the best recovery than the CellSearch system. Morris et al. identified hepatocellular CTCs in 19 out of 19 (100%) patients by ISET methodology and 14 out of 50 (28%) patients by Cell Search system suggesting the accuracy in sensitivity and specificity [35]. Khoja et al. [36] compared the detection of CTC in 54 pancreatic cancer patients with ISET and CellSearch system. The percentage of detection was higher; 93% by ISET and 40% by CellSearch. Pailler et al. [37] also concluded ISET methodology to be 100% sensitive compared to 33% with CellSearch in non-small cell lung cancer (NSCLC) patients. Another study conducted by Krebs et al. [38] explains the advantages and disadvantages of using both CellSearch and ISET approaches for a complementary role. CTC recovery rate with the ISET method was 95% and 80% compared to 52% and 23% with CellSearch; however, the results obtained were only from small patient groups of 10 and 40, respectively. In a direct comparison study of CellSearch and ISET, Farace et al. [39] discussed the limitation of using the EpCAM antigen (CellSearch assay) and cell size (ISET assay) in 20-patient cohorts for metastatic breast, prostate and non-small cell lung cancer. They concluded the ISET methodology to be a more accurate clinical tool for breast, prostate and non-small cell lung cancers. Hofman et al. [40] also compared the efficacy of CellSearch assay™ and the ISET methods in 210 patients undergoing radical surgery for non-small-cell lung carcinoma (NSCLC). They concluded that both methods were good prognostic markers for CTC detection in this patient group. CTC detection methods utilised in studies investigating head and neck cancers are summarised in Table 1. Due to their reported sensitivity and specificity, ISET and Maintrac methodology have been widely used for clinical utility at the NutriPATH, National Institute of Integrative Medicine (NIIM) and Genostics in Australia [41–43].
Table 1. Overview of head and neck circulating tumour cells studies.

| Author/Country          | Head and Neck Cancer Types and Staging | CTC/CCSC Markers                                                                 | Methodology                                                                 | Patient Treatment                                         |
|-------------------------|----------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------|
| Kulasinghe, Zhou et al. Australia [44] | Stage I–IV                             | CTC clusters, DAPI, cytokeratin EGFR, anti-CD45                                  | Straight microfluidic chip                                                  | treatment naive                                          |
| Kulasinghe, Kapeleris et al. Australia [45] | Stage I–IV                             | CTC clusters, PD-L1, ALK, EGFR, DAPI, anti-CD45                                  | ClearCell FX system CTChip® (Clearbridge Biomedics, Singapore)              | treatment naive                                          |
| Kulasinghe, Schmidt et al. Australia [46] | Stage I–IV                             | CTC clusters, DAPI, cytokeratin EGFR, anti-CD45                                  | Spiral, microfluidic chip technology                                        | treatment naive                                          |
| Kawada, Takahashi et al. Japan [47] | TNM I–IV                               | anti-cytokeratin (CK) 8, 18 and 19, anti-epithelial cell adhesion molecule (EpCAM), and anti-CD45 | cell sieve low pressure micro filtration assay                              | surgery and chemo radiotherapy                          |
| Fanelli, Oliveira et al. Brazil [48] | Locally advanced head and Neck Squamous cell carcinoma | CTM- TGF-βRI                                                                  | ISET Method                                                                  | adjuvant chemo radiotherapy; definitive radiotherapy (RT) concurrent with chemotherapy or cetuximab, or induction chemotherapy followed by RT concurrent with chemotherapy or cetuximab |
| Kulasinghe, Perry et al. Australia [49] | Supraglottal squamous cell carcinoma (SCC) | PD-1/PD-L1                                                                     | CellSearch System (Janssen Diagnostics) and shear spiral microfluidic technology | single case study who do not respond to 1st/2nd line chemo-radiotherapy |
| Kulasinghe, Tran et al. Australia [3] | TNM0M0, T2/T3 (71%) and either no nodal spread N0 (50 (T4N2b)) | CTC clusters, KCC and DNA FISH for EGFR DAPI Cytokeratin | shear spiral microfluidic technology                                         | chemotherapy lung metastasis findings                   |
| Kulasinghe, Kenny et al. Australia [11] | T4 (55.1%) to advanced nodal spread (N2A-C) (62.1%). | CD45 APC, DAPI, CK-PE                                                          | CellSearch® platform, ScreenCell® (microfiltration device, France and RosetteSep™ (negative enrichment)) | chemotherapy docetaxel, cisplatin and 5-fluorouracil      |
| Kulasinghe, Perry et al. Australia [50] | Advanced HNC clinical stage patients ranging from T3N0 to T4aN2b. | Cytokeratin 8, 18, 19, CD45 and DAPI                                           | RosetteSep™ Human CD45 depletion cocktail (Stemcell Technologies™, Vancouver, BC, Canada), CTC culture for therapeutic screening | showed high CTC counts than EpCAM Cellsearch® in HPV + patients |
| Patel, Shah et al. India [29] | Oral squamous cell carcinoma (OSCC) | CCSC CD44v6 and Nanog                                                          | CD44+ FITC labelled antibody by immuno-magnetic cell separation technique     | CCSC resistance to Cisplatin                            |
| Moroisin, Ashford et al. Australia [51] | Metastatic cutaneous squamous cell carcinoma affecting the lymph nodes of the parotid and/or neck | EpCam and cytokeratin                                                         | Ficoll-Paque PLUS (GE Healthcare, NSW, Australia), IsoFluxTM immunomagnetic beads with Anti-EpCAM antibodies; CTC Enrichment kit Fluo Biosciences Inc. System, Alameda, CA, USA | surgical treatment                                      |
| Wu, Mastronicola et al. France [52] | Oral squamous cell carcinoma T4N2M0 | EGFR neg CK PE-cytokeratin phycocerythrin DAPI CD45 APC EGFR                    | CellSearch® system                                                           | rare case study pre-operative: intra-operative: and post-operative                         |
| Li, Liu et al. China [53] | Nasopharyngeal carcinoma (NPC) early TNM stages, Tumour stage I-IV | CD45 DAPI                                                                      | Anti CD45 antibody conjugated immuno-magnetic beads (Cytel, Jiangsu, China)  | chemo radiotherapy treatment                           |
## Table 1. Cont.

| Author/Country | Head and Neck Cancer Types and Staging | CTC/CCSC Markers | Methodology | Patient Treatment |
|----------------|----------------------------------------|------------------|-------------|-------------------|
| Hsieh, Lin et al. Taiwan [54] | Locally advanced, recurrent, or initially metastatic HNSCC TNM II–IV | EpCAM/ podoplanin-PDPN | Power Mag immunofluorescence | Prechemotherapy Healthy donors |
| Inhestern, Oertel et al. Germany [31] | TNM III–IV | EpCAM | Laser scanning cytometry | PB/before/during/surgery radiotherapy, chemo radiotherapy |
| Grisanti, Almici et al. Italy [55] | TNM III–IV | EpCAM/CD45/DAPI | CellSearch | PB/before/during |
| Weller, Nel et al. Germany [56] | TNM I–IV | CK/CD45/DAPI | Immunofluorescence | PB/before treatment |
| Tinhofer, Konschak et al. Germany [57] | TNM I–IV | EGFR mRNA | RT-PCR | PB/before treatment |
| Gröbe, Blessmann et al. Germany [58] | TNM I–IV | EpCAM/CD45/DAPI | CellSearch | PB/before treatment |
| Bozec, Ilie et al. France [59] | TNM III–IV | EpCAM/CD45/DAPI | CellSearch | PB/before treatment |
| He, Li et al. China [60] | TNM III–IV | EpCAM/CD45/DAPI | CellSearch | PB/before treatment |
| Buglione, Grisanti et al. Italy [61] | TNM I–IV | EpCAM/CD45/DAPI | CellSearch | PB/before treatment |
| Nichols, Lowes et al. Britain [62] | TNM III–IV | EpCAM/CD45/DAPI | CellSearch | PB/before treatment |
| Balasubramanian, Lang et al. USA [63] | Head and neck cancer patients | EGFR cytokeratin, DAPI | NH₄Cl and CD45 negative Immunomagnetic separation | surgical resection |
| Hristozova, Konschak et al. Germany [64] | TNM I–IV | EpCAM, CK | Flow cytometry | PB/before treatment |
| Jatana, Balasubramanian et al. USA [65] | TNM I–IV | CK, CD45, DAPI | Immunocytochemistry | PB/before treatment |
| Toyoshima, Vairaktaris et al. USA [66] | TNM I–IV | CK20 | RT-PCR | PB/after treatment |
| Mollaoglu, Vairaktaris et al. Greece [67] | Oral squamous cell carcinoma (OSCC) TNM I–IV, for the early detection of metastatic cells | Melanoma Associated Antigen– (MAGE A1, 2, 4 and 12) | disseminated tumour cell detection by bDNA technology. | Before treatment had floor of the mouth tumors |
| Yang, Lang et al. USA [68] | squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx | EGFR, DAPI | NH₄Cl and CD45 negative Immunomagnetic separation | surgical resection for patients who have not been previously treated for this disease. |
| Balasubramanian, Yang et al. USA [69] | Head and neck cancer patients | 8, 18, 19 cytokeratins CD45, CD44, EpCAM Vimentin N-cadherin | NH₄Cl and CD45 negative Immunomagnetic separation | surgical resection |
| Winter, Stephenson et al. Australia [70] | Advanced head and neck cancers | ELF3, CK19, EGFR and EphB4 | Immunomagnetic enrichment, RT-PCR | time of surgery |
| Güney, Yoldas et al. Turkey [71] | TNM I–IV | EpCAM | magnetic cell separation MACS | PB/before treatment |
| Wollenberg, Walz et al. Germany [72] | TNM I–IV | CK 19 | IHC- alkaline phosphatase-anti-alkaline phosphatase (APAAP) | BM/before treatment |
| Wirtschafter, Benninger et al. USA [73] | TNM I–IV | CK 20 | Immunocytochemistry | PB/before treatment |

EpCAM: Epithelial cell adhesion molecule, CK-cytokeratin, Immunohistochemistry, NH₄Cl-Ammonium Chloride, PB-Peripheral blood, BM-bone marrow, CD-cluster of differentiation, RT-PCR, reverse transcription–polymerase chain reaction, TNM-Tumour nodal metastasis.
3. Radiotherapy Response on Circulating Tumour Cells, ctDNA and cfDNA

To date, there have only been a few published studies investigating the impact of radiation therapy on CTCs [24,51,61,63,69,74,75]. In HNSCC, Buglione et al. [61] investigated the role of CTC in patients receiving radiotherapy alone; however, the results were grouped with patients who had also received chemotherapy and the sensitivity was low (30%) [61]. Radiotherapy in combination with chemotherapy has shown reduction in HNSCC and prostate CTC [51,61,65,70,75–78]. Research indicates radiotherapy makes the tumour cells more aggressive and potentiates the circulation of non-small lung cancer (NSCLC) cells [24]. The successful use of conventional fractionated high-dose radiotherapy (~2Gy per fraction for 30 days) can result in the destruction of clonogenic tumour cells through DNA damage and cell cycle arrest [24], through to mitotic catastrophe, apoptosis, necrosis, or autophagy [79–81], depending on the dose. Cellular radioresistance and radiosensitivity depends on cell type and origin, cell cycle, and the genetic background. Martin et al. [24] indicated an increase in CTC counts during early phase radiotherapy. Dorsey et al. [74] measured human telomerase reverse transcriptase (hTERT) activity specific to cancer cells as a threshold for live CTC positivity in NSCLC patients receiving radiotherapy. Lowes et al. [75] also reported that CTC could be used as a predictive biomarker in clinical decision making for radiotherapy favourable prostate cancer patient group. Our research group [14,15] reported the significance of favourable hyperbaric oxygen therapy for chronic radiation-induced tissue injuries. Administering low-dose cisplatin, compared to a high-dose treatment regimen, was well tolerated when used in combination with radiotherapy in head and neck cancer patients. Both of the studies in Figures 1 and 2 comprise the basis of the research expertise and the scope for assessing the influence of CTCs when using radiotherapy and chemoradiotherapy.

More recently, blood-based prognostic and predictive biomarkers for radiotherapy have drawn much attention and excitement in radiation oncology. In this section, we reviewed and explored all the noted uses of HNSCC circulating tumour DNA (ctDNA) for radioresistance and radiosensitivity diagnostic approaches.

Primary tumour information and metastases at different sites within the same patient may have different genomic characteristics due to tumour heterogeneity [82]. Therefore, tumour biopsy alone, which is currently used in clinical practice, may not reveal sufficient information for radiotherapy response decision-making. Combining ctDNA and cell-free DNA (cfDNA) genetic information in radiation oncology can complement the current available technologies for future radiosensitising therapeutic intervention. However, evidence has shown that there is a radiation risk from CT scans inducing malignancy, suggesting that it may not be an ideal method for early cancer detection [83].

cfDNA is unstable and short-lived in the bloodstream [84–87], having a mix of malignant and non-malignant cell properties. It is released into the circulation through apoptotic and necrotic cell death mechanisms [85,88–90]. The DNA are short fragments of 166 bp sizes in low concentration. Increase in cfDNA level suggests the presence of residual tumour cells in plasma [91]. Interestingly, both mitochondrial DNA (mtDNA) and genomic DNA (gDNA) constitutes the total cfDNA [90]. The circulation of nucleosome, mutations, methylation, chromatin modifications, and viral DNA, like human papillomavirus (HPV), hepatitis B virus (HBV), and Epstein–Barr virus (EBV) in cfDNA has the potential to monitor the anticancer therapy response in nasopharyngeal cancer and head and neck cancer [92–100]. In some clinical studies, the increase in cfDNA fragments in blood plasma and serum has been associated with poor prognosis [90].

Protein-based circulating biomarkers are specific to one cancer type, and it is not feasible to compare and generalise this to all cancer types [101]. On the other hand, ctDNA and cfDNA [17,101,102] in all cancer types accumulate somatic mutations, which can be correlated with any cancer type treatment regimens [17,101]. In metastatic breast cancer patients, Dawson et al. [87] measured the ctDNA mutant allele fraction and identified progression 5 months before imaging, suggesting that ctDNA quantification is more beneficial than imaging [87]. Other authors have suggested that ctDNA should be considered for clinical use in post-treatment follow-up of early stage cancer patients in whom there is no or minimal residual disease, given the higher sensitivity of such assays [103,104].
Next-generation sequencing technology platforms for ctDNA analysis was developed 20 years ago [105–108] as either targeted or untargeted approaches. Targeted approaches include BEAMing Safe-SeqS, TamSeq, and digital PCR, RTq PCR [109] to detect single-nucleotide mutations for limited genome regions, focusing on predefined gene hot spots like BRAF, KRAS and EGFR. The untargeted approach focuses on whole exome sequencing (WES) and whole genome sequencing (WGS) for screening genomic aberration by hypomethylation [110] insertions or deletions, acquired by therapy resistance. Murtaza et al. [111], using exome-wide analysis, quantified very high ctDNA levels for 1 to 2 years in 6 cancer patients and also reported on several mutations confirming drug resistance acquired post-treatment [111]. More recently, a novel method called cancer personalized profiling by deep sequencing (CAPP-seq) has demonstrated the advantage of combining the untargeted and targeted approaches, which can then be generalised to all types of cancers with high specificity [105].

The major advantage of ctDNA application in radiation oncology is studying the tumour kinetics for radiotherapy response assessment. Until now, using CAPP-Seq has differentiated the normal and residual disease ctDNA changes in NSCLC patients treated with fractionated and stereotactic ablative radiotherapy [105]. Alternatively, ctDNA usage can be applied to patients developing symptoms or perform imaging when there is a rise in the ctDNA levels.

![Figure 1. PET scan of Male pyriform fossa squamous cell carcinoma stage T4aN2bM0 patient without surgery, treated with radical radiotherapy delivery 70Gy/35# over 7 weeks followed by cisplatin 100 mg/msq given on week 1, week 4 and week 7 of radiotherapy. (A) Left panel blue circle showing the tumour spot before treatment on the 23 October 2014; (B) Right blue circle panel showing the antitumor effect of radical radio chemotherapy after treatment, showing no regional palpable lymphadenopathy, oral capsule was clear, showing no local recurrence, patient follow up after two years on 11 May 2017.](image-url)
Figure 2. CT scans of the neck region in pyriform fossa squamous cell carcinoma patient showing the tumour area and no local recurrence. (A) Right panel blue circle showing clear palpable lymphadenopathy. (B) Left panel blue circle showing the tumour regression after two years, nasendoscopy also showed no local recurrence.

Measuring Circulating Epstein Barr virus (EBV) DNA and human papilloma virus (HPV) DNA in HNSCC patients can be used as a biomarker for before and after radiotherapy and chemo-radiotherapy response. Successful radiotherapy treatment should decrease the level of circulating EBV and HPV DNA [97,98,100,106–108,112]. In a different paradigm, where ctDNA levels remained stable and post-treatment imaging revealed complete response for radiation therapy, months later, a patient developed metastases in multiple organs, suggesting ctDNA level was an indicator of micrometastatic disease progression [101]. Lo et al. [98] observed that plasma EBV DNA increased in the first week of radiation therapy and subsequently decreased in nasopharyngeal carcinoma patients. Thus, ctDNA kinetics as a biomarker could help clinicians deliver tailored radiotherapy and/or adjuvant systemic therapy for individualised treatment rather than following a one-size-fits-all approach [98,99].

Currently, only clinical radiotherapy imaging data, as indicated in Figures 1A,B and 2A,B, guide clinicians in treatment response when using radiotherapy alone in HNSCC patients. Towards precision medicine in radiation oncology, CTC counts, ctDNA and cfDNA, along with medical imaging modalities, will play a beneficial role in predicting patient prognosis.

4. CTC Lines, CCSC Derived CSC Organoids for Future Tailored Radiotherapy

CTC culturing for functional studies from cancer patients is logistically challenging. Currently, for understanding CTC, CCSC biology and tumour heterogeneity, all race cell lines or preclinical models for developing new efficient novel drugs are not commercially available [113]. Functional analysis involves understanding the viable CTCs metastatic-initiating potential using in vitro and in vivo models [114–118]. Based on the existing HNSCC chemo-radiotherapy literature, it is
expected that no isolated CTCs using different methodologies post-treatment can be cultured in vitro. Cayrefourcq et al. [115] established the first CTC permanent cell line from the blood sample of a colon cancer patient and validated the tumour-forming capacity in SCID mice [115]. Interestingly, it shared similar characteristics to those of the primary tumour, possessing epithelial stem-like features. In a heterogeneous population of cells in circulation, very few, depending on the genetic makeup, can be cultured successfully for real-time assessment of radiotherapy treatment. Until now, very few studies have validated HNSCC CTC expansion and culturing as tumour spheres [3,11,50,119].

Cancer stem cells (CSCs) are cells possessing self-renewal properties with high metastatic potential and resistance to therapies. The major reason for treatment failure in anticancer therapy modalities is due to the presence of CSCs. CTCs expressing stem cell markers in the circulation are known as circulating cancer stem cells (CCSCs) and are highly tumorigenic compared to tissue CSCs [120]. CSCs and non-CSCs possess common invasive/migratory features such as epithelial-mesenchymal transition. Regarding CCSC, Patel S et al. [29] explored the role of CD44v6 and Nanog stem cell markers in oral squamous cell carcinoma population. Commonly used CSC markers like CD133, CD44 and ALDH were associated with poor patient outcome. Among them, CD44 is highly expressed in HNSCC cancer stem cells and circulating cancer stem cells. The over-expression of CD44+ and CD133+ cells provides resistance in tumours and the capability for disease relapse after chemo/radiotherapy in immunodeficient mice [121]. Therefore, selective targeting of these markers should be utilised to deliver cytotoxic drugs to CSCs, as one Wnt pathway antagonist (sFRP4) in HNSCC CSCs decreased CD44, ALDH, ABCG2 and ABCC4 drug-resistance expression [122]. Furthermore, detailed head and neck cancer CSC biomarkers and their transcription factors are reviewed as CD44, CD133, ALDH, cMET and Oct-4, Nanog, Sox2, respectively [123,124].

With regard to HNSCC HPV status, HPV-positive patients responded to radiation treatment better when compared to HPV-negative patients. Vlashi et al. [125] tested the CSC hypothesis to inherent radiosensitivity and radioresistance in HPV-positive and -negative HNSCC cell lines. HNSCC HPV-positive and -negative status CSC demonstrated radiation effects that were similar to HNSCC HPV-positive and -negative cell lines results. Additionally, radiotherapy induced the dedifferentiation of head and neck cancer cells into stem cells and increased plasticity by Yamanaka reprogramming factors (transcription factors Oct4 (Pou5f1), Sox2, cMyc and Klf4) in HPV-negative cell lines [125].

In summarising the literature, the CCSC findings from several studies reveal that CTCs from head and neck, lung, breast and prostate cancer can be cultured as spheroids or organoids for more than 6 months, and these CTCs possess self-renewal cancer stem cell properties and exhibit a radioresistant and chemoresistant phenotype with a high metastatic potential [109,120,126–129]. Recently, binding sites for OCT4, NANOG, SOX2 and SIN3A in breast cancer CTC clusters were shown to be hypomethylated to what is seen in embryonic stem cell biology [110].

The authors suggested the CD44+ CSC-like cell population possessed dose-dependent resistance to cisplatin in the peripheral blood circulation as do CCSC [29]. The same group again reported the anticancer effect of curcumin inhibiting the stem cell features (self-renewal potential) of non-small cell lung carcinoma CCSC [130]. Recently, another group, Zhang S et al., compared the metastatic and invasiveness characteristics of circulating gastric cancer stem cells (GCSCs) and tissue gastric cancer stem cells (TGSCCs) in human gastric adenocarcinoma patients [131]. Interestingly, Chen et al. [132] reported that GCSCs showed greater aggressive phenotype to TGSCCs when isolating GCSCs and TGSCCs from blood and tissue of gastric adenocarcinoma patients. They also successfully developed in vitro cell culture expansion with the same phenotype for several passages [132]. In a correlation study of CTC and CCSC from non-metastatic breast cancer patients, CTC was considered to be more appropriate for therapy assessment and CCSC as an independent prognostic marker for treatment failure and tumour recurrence [133]. Similar findings were reported for use of CD133 and CD44v9 CSC markers for predicting recurrence, prognosis, and treatment efficacy in colorectal cancer patient CTCs [134–136].
Kantara C et al. also developed a novel diagnostic assay, expressing CSC markers (DCLK1/LGR5) with CD44/Annexin A2 for detecting colon cancer CCSCs in the blood of colonic adenocarcinomas patients [137]. Similarly, Grillet F, et al. [138] developed a colorectal cancer (CRC)-expressing cancer stem cell phenotype for drug testing and monitored the metastatic potential in the real world for clinical practice. The outcome of the study is now in clinical trial registration (ClinicalTrial.gov NCT01577511) for individualised treatment [138]. Interestingly, a patent-pending study on doxorubicin and aspirin as low dose combination therapy in patient-derived CTC clusters reduced CD 44 and 24 CSCs and tumour relapse [139].

5. Head and Neck Cancer Treatment Modalities and Application

Management of head and neck cancers to date has relied on the conventional treatments of surgery, radiotherapy and chemotherapy. Initiating treatment of this group of cancers by a molecular approach is innovative, and currently there is limited evidence available regarding the effects of CTC concentration during radiotherapy treatment to gauge responses and modify radiation doses. The CTC genes regulating the radiotherapy kinetics (including dose rate and total dose) have not been identified to date with particular applications of radiosensitivity and radioresistance. Furthermore, CTC gene expression changes after radiotherapy, and chemotherapy management is still in the infancy stages of discovery. At present, much of the work done has been focused on signalling pathways.

Deregulated signalling pathways contribute to oncogenic cellular transformation and resistance. Several gene therapy strategies with different vector delivery mechanisms are being investigated in clinical trials for HNSCC in the UK [140–143]. Radiotherapy with gene therapy will be a novel approach to treat HNSCC in the future [144,145]. Gene expression profiling and identification of biomarkers will further complement the current major clinicopathologic challenges, including staging, lymph node, and distant metastasis, treatment choice and patient outcome. In 2007, the Netherlands Cancer Institute (NKI), using NKI array method determined the gene expression profile as a good prognostic value for chemo-radiotherapy (cisplatin-based) in Phase II and randomized Phase III trials of advanced HNSCC patient group [146]. Later, 10 hub genes (AR, c-Jun, STAT1, PKC-β, RelA, cABL, SUMO1, PAK2, HDAC1 and IRF1) were developed using a system biology-based gene expression classifier for regulating radio-sensitivity genomic adjusted radiation dose (GARD) [147], including the radiation response of DNA damage, histone deacetylation, cell cycle regulation, apoptosis and proliferation [148–150].

In a collaborative study in 2009 between the Moffitt Cancer Centre, Research Institute USA and the Netherlands Cancer Institute, the multigene expression model for predicting the intrinsic tumour radiosensitivity and treatment response in patients was developed [151]. Subsequently, Torres-Roca et al. measured the GARD values [147] in 8271 primary tissue samples consisting of 20 different disease sites. The GARD values ranged from (1.66 to 172.4). Gliomas and sarcomas resulted in lower values and cervical and oropharyngeal HNSCCs resulted in higher values. The GARD approach emphasises only the radiosensitivity parameters with the potential for further optimising the current radiation dose, using tumour-specific genomic data as a novel genomic radiotherapy prescription framework [152]. Conventional HNSCC radiotherapy treatment guidelines currently follow a ‘one size fits all’ modality, guided by the TNM staging system, which is currently under review. The new 8th Edition TNM staging takes into account oropharyngeal p16 positive cancer, which is down-staged accordingly to move away from the ‘one size fits all approach’. Along with precision medicine tools such as genomics, radiomics and mathematical modelling, the GARD approach could open new doors in reducing toxicity and improving patient outcome. Supplementing the GARD approach with information gained by CTC genomics could further guide personalized treatment by tailoring radiotherapy dose modifications to individual patients. Understanding the role of EGFR in HNSCC metastasis and treatment efficacy is essential for improving treatment outcomes [153–157]. Often, patients with drug resistance EGFR mutations are limited to treatment with tyrosine kinase inhibitors to target the epidermal growth factor receptor gene (EGFR) [154]. Monitoring HNSCC CTCs and their
expression of EGFR and pEGFR in the blood has been implicated as a good predictor for radio-chemo therapy response [55,57]. Studies have shown that CTC concentration increased in the presence of radiotherapy in stage IVA/B, HNSCC patients. However, addition of cetuximab decreased the CTC number compared to cisplatin/5-fluorouracil. The treatment was also effective in decreasing the pEGFR expression [158]. Overall, EGFR status can be used as a chemo-radiotherapy and radiotherapy indicator along with other CTC epithelial markers like EpCAM and cytokeratin. Evidence also proves that EGFR plays a vital role in maintaining the HNSCC CTC clusters (possessing the stem cell features) showing metastatic potential. Targeting EGFR in these clusters might lead to a more precise treatment approach.

Gemmill et al. and Wagner et al. [159,160] critically reviewed the novel usage of Cetuximab for HNSCC in a large randomised Phase III clinical trial. Cetuximab in combination with radiotherapy showed good loco-regional control compared to radiotherapy alone with less acute toxicity by inhibiting epidermal growth factor receptor (EGFR) [159–161]. Later, Tinhofer et al. showed a decrease in CTC number in combination with radiotherapy [158]. Cisplatin (cis-diammine-dichloro-platinum\(\text{II}\)) is a cytotoxic drug currently used in the treatment of several cancers and is effective through causing DNA damage or apoptosis of tumour cells. The usage of cisplatin as a radiation sensitisier in the treatment of advanced HNSCCs are summarised in phase II clinical trials [162–168]. From an Australian radiotherapy perspective, our own research group conducted a retrospective study that showed the efficacy and tolerability of cisplatin in HNSCC patients receiving radiotherapy treatment. [15]. An ongoing international randomised controlled trial being run by the Trans-Tasman Radiation Oncology Group (TROG 12.01—HPV Oropharynx) is comparing the side-effects of cetuximab versus cisplatin, as they both possess different antitumor effects on radiation therapy. In an American randomised phase III trial (RTOG 0522), the outcome did not improve when cetuximab was combined with cisplatin and delivered concurrent with radiotherapy [169]. Similar studies utilising the hypoxic cytotoxin tirapazamine combined with cisplatin and radiation have been performed, including the TROG 02.02 Phase III “HeadSTART” trial, which did not find any significant improvement in outcome for head and neck cancer patients [170]. In a Phase III Danish Head and Neck Cancer Study (DAHANCA), hypoxic radiosensitizer Nimorazole (Nimoral) was found to significantly improve the hypoxic radio-sensitisation of supraglottic laryngeal and pharyngeal carcinoma with minimal side effects [171]. Nimorazole is currently being investigated in the EORTC 1219 ROG-HNCG TROG 14.03 trial using the 15 hypoxic gene signature in HPV/p16-negative SCC patients to identify hypoxic cell signature for radiotherapy treatment outcomes.

6. Targeting CTC by Wnt Signalling for Radio Ligand-Based Therapies

Wnt signalling plays a significant role in radio resistance. To our knowledge, the role of radio resistance and the Wnt signalling mechanism is not yet elucidated in any of the cancer circulating tumour cells and its associated circulating cancer stem cells. There is, however, limited literature regarding Wnt signalling in circulating tumour cells. Some data exist surrounding the non-canonical CTC gene signatures and WNT2 candidate gene in pancreatic CTC, Wnt expression contributing to antiandrogen resistance by single cell analysis RNA-seq in prostate CTCs [172–174].

Since 1997, our research group has extensively published on Wnt signalling and the role of secreted frizzled related protein (sFRP4) and its associated domains, cysteine rich domain (CRD) and netrin-like domain (NLD) as an antiangiogenic protein in various cancers such as brain, breast, ovary, prostate, mesothelioma, including HNSCC CSCs and now recently in reproductive CSCs of breast, prostate and ovary [122,175–187]. Jun et al. [188] explored the molecular mechanism of Wnt signalling-induced radioresistance and DNA double-strand break repair by LIG4-DNA ligase through β-catenin in colorectal cancer.

Based on our published data, we hypothesise the sFRP4 and its associated domains CRD and NLD will modulate the WNT 3a gene expression-induced radioresistance in HNSCC CTC and CCSCs and could reverse the effect of radioresistance. By diligently moving forward one step at
a time, this potent and selective inhibitor may assist drug discovery and has potential to reverse the
effect of radioresistance by targeting human HNSCC-derived CTCs and CCSCs resulting in a novel
radiotherapy breakthrough for anticancer therapeutic modalities in the clinic [122,176,183,184,188].

From a clinical perspective, a high level of nuclear β-catenin accumulation was detected in
colorectal cancer, HNSCC [189,190], ionizing radiation-induced glioblastoma [191] and in CTCs of
prostate and breast cancer and myeloid leukaemia. Targeting β-catenin is also a promising therapeutic
approach in overcoming radioresistance [192–194]. Interestingly, with respect to the CSC hypothesis, a
Wnt signalling pathway member leucine-rich repeat-containing G-protein coupled receptor 5 (LgR5)
showed significance in oesophageal adenocarcinomas (EAC) with and without Barrett’s Oesophagus
(BE) [195].

c-Met is frequently altered in 90% of HNSCC tumours by mutation and overexpression
contributing to HGF/cMet signalling [196–199]. Several anticancer tyrosine kinase inhibitors
and the ongoing clinical trials targeting HGF and c-Met receptor are summarised by
Rothenberger NJ et al. [196] Cetuximab (PF-2341066) is a tyrosine kinase inhibitor that when used
in combination with docetaxel and cisplatin showed synergistic antitumor effects in HNSCC CSCs
in a patient-derived xenograft (PDX) model [197,199]. Previous findings show crosstalk between
inhibiting cMET and WNT signalling. Furthermore, as proof of concept Sun et al. reported
on the role of c-Met/FZD 8 in inhibition of patient derived CSC-like cells by selective c-MET
inhibitor PF-2341066 [197]. Thus, use of c-MET inhibitors for antagonising Wnt signalling in
HNSCC CSCs is warranted. Another interesting finding which may be also relevant to HNSCC
CTC detection is that highly sensitive (80%) c-MET FISH-based platforms have been seen in gastric,
pancreatic, colorectal, bladder, renal, and prostate cancers [198]. Studies have shown that few
EGFR inhibitor-positive HNSCC patients treated with routine cetuximab also acquired resistance to
c-MET [200,201]. Developing β-catenin and c-MET-based techniques will also contribute to enhancing
the sensitivity of the current established CTC detection methods and aim to improve the survival
of HNSCC patients. The overall prospects of HNSCC CTCs research in radiation oncology
and progressing towards unexplored CTC-cancer research are summarised in Figures 3 and 4.

---

**Figure 3.** Potential of head and neck circulating tumour cell research in radiation oncology.
C-MET FISH-based platforms have been seen in gastric, pancreatic, colorectal, bladder, renal, and prostate cancers [198]. Studies have shown that few EGFR inhibitor-positive HNSCC patients treated with routine cetuximab also acquired resistance to c-MET [200,201]. Developing β-catenin and c-MET-based techniques will also contribute to enhancing the sensitivity of the current established CTC detection methods and aim to improve the survival of HNSCC patients. The overall prospects of HNSCC CTCs research in radiation oncology and progressing towards unexplored CTC-cancer research are summarised in Figure 3; Figure 4.

Figure 4. New developments and progress towards unexplored CTC-Cancer research. Figure generated using free smart draw templates and examples program.

7. Conclusions and Future Directions

This review article provides mounting evidence and scope for using CTC counts, CTC-derived CCSC and ctDNA as a prognostic and predictive marker for current head and neck individualised radiotherapy and chemo-radiotherapy response. Tracking CTC counts during radiotherapy treatment will measure the outcome and disease resistance leading to recurrence especially in loco regionally advanced disease with a significant potential for clinical application. In future, it may also set the stage for developing CTC radiosensitive index by GARD in the clinical setting for tailored radiotherapy dose prescription clinical practice. Today cost effective NGS and other sequencing platforms can also guide the radiotherapy genomic alterations response. Our group is currently developing CTC, circulating cancer stem cells and imaging guided genetic information (model) framework for radiotherapy resistance and sensitivity in HNSCC for clinical practice. We are confident that the proposed research will also contribute to the development of new therapeutic strategies for radiotherapy precision medicine. Identification of radiotherapy/chemo-radiotherapy relapsed HNSCC CTC and CCSC subpopulation and associated genetic material will be a valuable clinical tool to improve the current treatment approach for this disease. Developing a less invasive CTC, CCSC as a prognostic and predictive marker will be of added advantage in clinical practice for sequential radiotherapy and chemo-radiotherapy assessment. Furthermore, investigating WNTs, c-Met, PBK, AKT/mTOR, CCSC epithelial markers and stem cell markers in radiotherapy HNSCC CTCs has the potential to generate future radio-sensitisation modalities. Globally, current drug discovery is an expensive and time-consuming process with high failure rates in patients. Future studies investigating CTCs on early and advanced cancer models offer a less invasive approach compared to tissue biopsies and can facilitate further understanding of tumour heterogeneity. The aim is to tailor treatment to individual patient requirements based on information gained by conducting chemo-radiation testing on their own CTC/CCSC organoids. This would then identify the most suitable FDA-approved chemo-radiation regimen for their particular cancer. Using the advanced CTC/CCSC organoid models, resistance and sensitivity rate can be predicted for therapy response prior to administering the therapy to the patients, avoiding unwanted toxicity burden. Patient CTC organoids approach in the real world is faster and less expensive with more control than animal models. Our goal is to introduce CTC/CCSC as companion diagnostics and clinical intervention for current available treatment prediction. Identifying and targeting specifically the CSC in CTC using surface markers and
combining with radiotherapy will be major advancements in the field of cancer research. Introducing such robust platform discoveries and translating it to human research in radiotherapy treatment will help resolve the current challenges of potentially incurable cancer recurrence.

**Funding:** Radiation Oncology Department, Sir Charles Gairdner Hospital (SCGH), comprehensive cancer centre, North Metropolitan Health Service and Curtin University Medical School Strategic Research Funds.

**Acknowledgments:** The authors wish to thank William Hart, Dean of Curtin Medical School for arranging the four way collaboration between Radiation Oncology, Sir Charles Gairdner Hospital, Cancer Centre, Nedlands, Perth WA, Australia; Medical Radiation Sciences, School of Molecular and Life Sciences, Curtin Health Innovation Research Institute, Curtin University; Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, and School of Public Health, Faculty of Health Sciences, Curtin University. Vanathi Perumal is a recipient of Sir Charles Gairdner Hospital (SCGH) radiation oncology clinical fellowship.

**Conflicts of Interest:** The authors declare they have no competing financial interests.

**References**

1. Dixit, R.; Weissfeld, J.L.; Wilson, D.O.; Balogh, P.; Sufka, P.; Siegfried, J.M.; Grandis, J.R.; Diergaarde, B. Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: Results from the pittsburgh lung screening study. *Cancer* 2015, 121, 1431–1435. [CrossRef] [PubMed]

2. Head and Neck Cancer Statistics. Available online: https://head-neck-cancer.canceraustralia.gov.au/statistics (accessed on 15 October 2017).

3. Kulasinghe, A.; Tran, T.H.P.; Blick, T.; O’Byrne, K.; Thompson, E.W.; Warkiani, M.E.; Nelson, C.; Kenny, L.; Punyadeera, C. Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. *Sci. Rep.* 2017, 7, 42517. [CrossRef] [PubMed]

4. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: Globocan 2008. *Int. J. Cancer* 2010, 127, 2893–2917. [CrossRef] [PubMed]

5. Network, C.G.A. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015, 517, 576. [CrossRef] [PubMed]

6. Shield, K.D.; Ferlay, J.; Jemal, A.; Sankaranarayanan, R.; Chaturvedi, A.K.; Bray, F.; Soerjomataram, I. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. *CA Cancer J. Clin.* 2017, 67, 51–64. [CrossRef] [PubMed]

7. Reports & Data. Available online: https://www.aihw.gov.au/reports-data (accessed on 14 March 2018).

8. Head and Neck Cancer. Available online: https://www.cancer.net/cancer-types/head-and-neck-cancer/view-all (accessed on 16 January 2019).

9. Seethala, R.R.; Stenman, G. Update from the 4th edition of the world health organization classification of head and neck tumours: Tumors of the salivary gland. *Head Neck Pathol.* 2017, 11, 55–67. [CrossRef] [PubMed]

10. Head and Neck Cancer. Available online: https://www.cancer.net/cancer-types/head-and-neck-cancer/introduction (accessed on 11 February 2019).

11. Kulasinghe, A.; Kenny, L.; Perry, C.; Thiery, J.-P.; Jovanovic, L.; Vela, I.; Nelson, C.; Punyadeera, C. Impact of label-free technologies in head and neck cancer circulating tumour cells. *Oncotarget* 2016, 7, 71223. [CrossRef] [PubMed]

12. Bibault, J.E.; Tinhofer, I. The role of next-generation sequencing in tumoral radiosensitivity prediction. *Clin. Transl. Radiat. Oncol.* 2017, 3, 16–20. [CrossRef] [PubMed]

13. Cancers Guidelines WiKi. Available online: https://wiki.cancer.org.au/australia/User:Joshua.dass (accessed on 20 November 2018).

14. Tahir, A.R.M.; Westhuyzen, J.; Dass, J.; Collins, M.K.; Webb, R.; Hewitt, S.; Fon, P.; McKay, M. Hyperbaric oxygen therapy for chronic radiation-induced tissue injuries: Australasia’s largest study. *Asia Pac. J. Clin. Oncol.* 2015, 11, 68–77. [CrossRef] [PubMed]

15. Ott, Z.; Skinner, M.B.; Dass, J.; Collins, M.; Mooi, J.; Thuraisingam, K.; Sabesan, S. Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients. *Asia Pac. J. Clin. Oncol.* 2011, 7, 287–292. [CrossRef] [PubMed]
16. Kim, K.Y.; McShane, L.M.; Conley, B.A. Designing biomarker studies for head and neck cancer. *Head Neck* 2014, 36, 1069–1075. [CrossRef] [PubMed]

17. Murlidhar, V.; Ramnath, N.; Nagrath, S.; Reddy, R.M. Optimizing the detection of circulating markers to aid in early lung cancer detection. *Cancers* 2016, 8, 61. [CrossRef] [PubMed]

18. Baumann, M.; Krause, M.; Overgaard, J.; Debus, J.; Bentzen, S.M.; Daارت, J.; Richter, C.; Zips, D.; Bortfeld, T. Radiation oncology in the era of precision medicine. *Nat. Rev. Cancer* 2016, 16, 234–249. [CrossRef] [PubMed]

19. Allard, W.J.; Matera, J.; Miller, M.C.; Repollet, M.; Connelly, M.C.; Rao, C.; Tibbe, A.G.; Uhr, J.W.; Terstappen, L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin. Cancer Res.* 2004, 10, 6897–6904. [CrossRef] [PubMed]

20. Brunner, T.B.; Kunz-Schughart, L.A.; Grosse-Gehling, P.; Baumann, M. *Cancer Stem Cells as a Predictive Factor in Radiotherapy*; Elsevier: Amsterdam, The Netherlands, 2012; pp. 151–174.

21. Jackson, S.P. Sensing and repairing DNA double-strand breaks. *Carcinogenesis* 2002, 23, 687–696. [CrossRef] [PubMed]

22. Roy, K.; Kodama, S.; Suzuki, K.; Watanabe, M. Delayed cell death, giant cell formation and chromosome instability induced by x-irradiation in human embryo cells. *J. Radiat. Res.* 1999, 40, 311–322. [CrossRef] [PubMed]

23. Siva, S.; MacManus, M.P.; Martin, R.F.; Martin, O.A. Abscopal effects of radiation therapy: A clinical review for the radiobiologist. *Cancer Lett.* 2015, 356, 82–90. [CrossRef] [PubMed]

24. Martin, O.A.; Anderson, R.L.; Russell, P.A.; Cox, R.A.; Ivashkevich, A.; Swierczak, A.; Doherty, J.P.; Jacobs, D.H.; Smith, J.; Siva, S. Mobilization of viable tumor cells into the circulation during radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 2014, 88, 395–403. [CrossRef] [PubMed]

25. Ashworth, T.R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. *Aust. Med. J.* 1869, 14, 146–147.

26. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. *Cancer Metastasis Rev.* 2013, 32, 367–378. [CrossRef] [PubMed]

27. Alix-Panabières, C.; Pantel, K. Challenges in circulating tumour cell research. *Nat. Rev. Cancer* 2014, 14, 623–631. [CrossRef] [PubMed]

28. Alix-Panabières, C.; Pantel, K. Circulating tumor cells: Liquid biopsy of cancer. *Clin. Chem.* 2013, 59, 110–118. [CrossRef] [PubMed]

29. Patel, S.; Shah, K.; Mirza, S.; Shah, K.; Rawal, R. Circulating tumor stem like cells in oral squamous cell carcinoma: An unresolved paradox. *Oral Oncol.* 2016, 62, 139–146. [CrossRef] [PubMed]

30. Kulasinghe, A.; Perry, C.; Jovanovic, L.; Nelson, C.; Punyadeera, C. Circulating tumour cells in metastatic head and neck cancers. *Int. J. Cancer* 2015, 136, 2515–2523. [CrossRef] [PubMed]

31. Inhestern, J.; Oertel, K.; Stemmann, V.; Schmalenberg, H.; Dietz, A.; Rotter, N.; Veit, J.; Görner, M.; Sudhoff, H.; Junghans, C. Prognostic role of circulating tumour cells during induction chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer. *PLoS ONE* 2015, 10, e0132901. [CrossRef] [PubMed]

32. Nagrath, S.; Sequist, L.V.; Maheswaran, S.; Bell, D.W.; Irimia, D.; Ulkus, L.; Smith, M.R.; Kwak, E.L.; Digumarthy, S.; Muzikansky, A.; et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature* 2007, 450, 1235–1239. [CrossRef] [PubMed]

33. Yu, M.; Stott, S.; Toner, M.; Maheswaran, S.; Haber, D.A. Circulating tumor cells: Approaches to isolation and characterization. *J. Cell Biol.* 2011, 192, 373–382. [CrossRef] [PubMed]

34. Kallergi, G.; Politaki, E.; Alkahtani, S.; Stournaras, C.; Georgoulas, V. Evaluation of isolation methods for circulating tumor cells (ctcs). *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* 2016, 40, 411–419. [CrossRef] [PubMed]

35. Morris, K.L.; Tugwood, J.D.; Khoja, L.; Lancashire, M.; Sloane, R.; Burt, D.; Shenjere, P.; Zhou, C.; Hodgson, C.; Ohtomo, T.; et al. Circulating biomarkers in hepatocellular carcinoma. *Cancer Chemother. Pharmacol.* 2014, 74, 323–332. [CrossRef] [PubMed]

36. Khoja, L.; Backen, A.; Sloane, R.; Menasce, L.; Ryder, D.; Krebs, M.; Board, R.; Clack, G.; Hughes, A.; Blackhall, F.; et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. *Br. J. Cancer* 2012, 106, 508–516. [CrossRef] [PubMed]
37. Pailler, E.; Adam, J.; Barthelemy, A.; Oulhen, M.; Auger, N.; Valent, A.; Borget, I.; Planchard, D.; Taylor, M.; Andre, F.; et al. Detection of circulating tumor cells harboring a unique alk rearrangement in alk-positive non-small-cell lung cancer. *J. Clin. Oncol.* 2013, 31, 2273–2281. [CrossRef] [PubMed]

38. Krebs, M.G.; Hou, J.M.; Sloane, R.; Lancashire, L.; Priest, L.; Nonaka, D.; Ward, T.H.; Backen, A.; Clack, G.; Hughes, A.; et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. *J. Thorac. Oncol.* 2012, 7, 306–315. [CrossRef] [PubMed]

39. Farace, F.; Massard, C.; Vimond, N.; Drusch, F.; Jacques, N.; Billiot, F.; Laplanche, A.; Chauchereau, A.; Lacrox, L.; Planchard, D.; et al. A direct comparison of cellsearch and iset for circulating tumour-cell detection in patients with metastatic carcinomas. *Br. J. Cancer* 2011, 105, 847–853. [CrossRef] [PubMed]

40. Hofman, V.; Ilie, M.I.; Long, E.; Selva, E.; Bonnetaud, C.; Molina, T.; Vénissac, N.; Mouroux, J.; Vielh, P.; Hofman, P. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: Comparison of the efficacy of the cellsearch assay™ and the isolation by size of epithelial tumor cell method. *Int. J. Cancer* 2011, 129, 1651–1660. [CrossRef] [PubMed]

41. RGCC Analyses. Available online: http://nutripath.com.au/?post_type=product&s=ctc (accessed on 14 March 2018).

42. Patient Information. Available online: http://www.genostics.com.au/ctccount (accessed on 14 March 2018).

43. Current Research Programs. Available online: https://www.niim.com.au/research-overview (accessed on 14 March 2018).

44. Kulasinghe, A.; Zhou, J.; Kenny, L.; Papautsky, I.; Punyadeera, C. Capture of circulating tumour cell clusters using straight microfluidic chips. *Cancers* 2019, 11, 89. [CrossRef] [PubMed]

45. Kulasinghe, A.; Kapeleris, J.; Kimberley, R.; Mattarollo, S.R.; Thompson, E.W.; Thiery, J.P.; Kenny, L.; O’Byrne, K.; Punyadeera, C. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. *Cancer Med.* 2018, 7, 5910–5919. [CrossRef] [PubMed]

46. Kulasinghe, A.; Schmidt, H.; Perry, C.; Whitfield, B.; Kenny, L.; Nelson, C.; Warkiani, M.E.; Punyadeera, C. A collective route to head and neck cancer metastasis. *Sci. Rep.* 2018, 8, 746. [CrossRef] [PubMed]

47. Kawada, T.; Takahashi, H.; Sakakura, K.; Ida, S.; Mito, I.; Toyoda, M.; Chikamatsu, K. Circulating tumor cells in patients with head and neck squamous cell carcinoma: Feasibility of detection and quantitation. *Head Neck* 2017, 39, 2180–2186. [CrossRef] [PubMed]

48. Fanelli, M.F.; Oliveira, T.B.; Braun, A.C.; Corassa, M.; Abdallah, E.A.; Nicolau, U.R.; da Silva Alves, V.; Garcia, D.; Calsavara, V.F.; Kowalski, L.P.; et al. Evaluation of incidence, significance, and prognostic role of circulating tumor microemboli and transforming growth factor-beta receptor i in head and neck cancer. *Head Neck* 2017, 39, 2283–2292. [CrossRef] [PubMed]

49. Kulasinghe, A.; Perry, C.; Kenny, L.; Warkiani, M.E.; Nelson, C.; Punyadeera, C. Pd-l1 expressing circulating tumour cells in head and neck cancers. *BMC Cancer* 2017, 17, 333. [CrossRef] [PubMed]

50. Kulasinghe, A.; Perry, C.; Warkiani, M.E.; Blick, T.; Davies, A.; O’Byrne, K.; Thompson, E.W.; Nelson, C.C.; Vela, I.; Punyadeera, C. Short term ex-vivo expansion of circulating head and neck tumour cells. *Oncotarget* 2016, 7, 60101–60109. [CrossRef] [PubMed]

51. Morosin, T.; Ashford, B.; Ranson, M.; Gupta, R.; Clark, J.; Iyer, N.G.; Spring, K. Circulating tumour cells in regionally metastatic cutaneous squamous cell carcinoma: A pilot study. *Oncotarget* 2016, 7, 47111. [CrossRef] [PubMed]

52. Wu, X.; Mastronica, R.; Tu, Q.; Faure, G.C.; De Carvalho Bittencourt, M.; Dolivet, G. A rare case of extremely high counts of circulating tumor cells detected in a patient with an oral squamous cell carcinoma. *BMC Cancer* 2016, 16, 552. [CrossRef] [PubMed]

53. Li, F.; Liu, J.; Song, D.; Zhang, Q.; Ding, N.; He, X. Circulating tumor cells in the blood of poorly differentiated nasal squamous cell carcinoma patients: Correlation with treatment response. *Acta Oto-Laryngol.* 2016, 136, 1164–1167. [CrossRef] [PubMed]

54. Hsieh, J.C.H.; Lin, H.C.; Huang, C.Y.; Hsu, H.L.; Wu, T.M.H.; Lee, C.L.; Chen, M.C.; Wang, H.M.; Tseng, C.P. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. *Head Neck* 2015, 37, 1448–1455. [CrossRef]

55. Grisanti, S.; Almici, C.; Consoli, F.; Buglione, M.; Verardi, R.; Bolzoni-Villarot, A.; Bianchetti, A.; Ciccarese, C.; Mangoni, M.; Ferrari, L. Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: Prognostic and predictive significance. *PLoS ONE* 2014, 9, e103918. [CrossRef] [PubMed]
56. Weller, P.; Nel, I.; Hassenkamp, P.; Gauler, T.; Schlueter, A.; Lang, S.; Dountsop, P.; Hoffmann, A.-C.; Leherrdt, G. Detection of circulating tumor cell subpopulations in patients with head and neck squamous cell carcinoma (hnscc). *PLoS ONE* 2014, 9, e113706. [CrossRef] [PubMed]

57. Tinhofer, I.; Konschak, R.; Stromberger, C.; Raguse, J.-D.; Dreyer, J.; Jöhrms, K.; Keilholz, U.; Budach, V. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck. *Ann. Oncol.* 2014, 25, 2042–2047. [CrossRef] [PubMed]

58. Gröbe, A.; Blessmann, M.; Hanken, H.; Friedrich, R.E.; Schön, G.; Wikner, J.; Effenberger, K.E.; Kluwe, L.; Heiland, M.; Pantel, K. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. *Clin. Cancer Res.* 2014, 20, 425–433. [CrossRef] [PubMed]

59. Bozec, A.; Ilie, M.; Dassonville, O.; Long, E.; Poissonnet, G.; Santini, J.; Chamorey, E.; Ettaiache, M.; Chauvière, D.; Peyrade, F. Significance of circulating tumor cell detection using the cellsearch system in patients with locally advanced head and neck squamous cell carcinoma. *Eur. Arch. Oto-Rhino-Laryngol.* 2013, 270, 2745–2749. [CrossRef] [PubMed]

60. He, S.; Li, P.; Long, T.; Zhang, N.; Fang, J.; Yu, Z. Detection of circulating tumour cells with the cellsearch system in patients with advanced-stage head and neck cancer: Preliminary results. *J. Laryngol. Otol.* 2013, 127, 788–793. [CrossRef] [PubMed]

61. Buglione, M.; Grisanti, S.; Almici, C.; Mangoni, M.; Polli, C.; Consoli, F.; Verardi, R.; Costa, L.; Paiaar, F.; Pasinetti, N. Circulating tumour cells in locally advanced head and neck cancer: Preliminary report about their possible role in predicting response to non-surgical treatment and survival. *Eur. J. Cancer* 2012, 48, 3019–3026. [CrossRef] [PubMed]

62. Nichols, A.C.; Lowes, L.E.; Szeto, C.C.; Basmaji, J.; Dhalival, S.; Chapeskie, C.; Todorovic, B.; Read, N.; Venkatesan, V.; Hammond, A. Detection of circulating tumor cells in advanced head and neck cancer using the cellsearch system. *Head Neck* 2012, 34, 1440–1444. [CrossRef] [PubMed]

63. Balasubramanian, P.; Lang, J.C.; Jatana, K.R.; Miller, B.; Ozer, E.; Old, M.; Schuller, D.E.; Agrawal, A.; Teknos, T.N.; Summers, T.A., Jr. Multiparameter analysis, including emt markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. *PLoS ONE* 2012, 7, e42048. [CrossRef] [PubMed]

64. Hristozova, T.; Konschak, R.; Stromberger, C.; Fusi, A.; Liu, Z.; Weichert, W.; Stenzinger, A.; Budach, V.; Keilholz, U.; Tinhofer, I. The presence of circulating tumor cells (ctcs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (scchn). *Ann. Oncol.* 2011, 22, 1878–1885. [CrossRef] [PubMed]

65. Jatana, K.R.; Balasubramanian, P.; Lang, J.C.; Yang, L.; Jatana, C.A.; White, E.; Agrawal, A.; Ozer, E.; Schuller, D.E.; Teknos, T.N. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: Initial results. *Arch. Otolaryngol. Head Neck Surg.* 2010, 136, 1274–1279. [CrossRef] [PubMed]

66. Toyoshima, T.; Vairaktaris, E.; Nkenke, E.; Schlegel, K.A.; Neukam, F.W.; Ries, J. Hematogenous cytokeratin 20 mrna detection has prognostic impact in oral squamous cell carcinoma: Preliminary results. *Anticancer Res.* 2009, 29, 291–297. [PubMed]

67. Mollaoglu, N.; Vairaktaris, E.; Nkenke, E.; Neukam, F.W.; Ries, J. Single disseminated tumor cell detection in peripheral blood sample of patients with oral squamous cell carcinoma using mage-a4. *Lab. Med.* 2009, 40, 665–668. [CrossRef]

68. Yang, L.; Lang, J.C.; Balasubramanian, P.; Jatana, K.R.; Schuller, D.; Agrawal, A.; Zborowski, M.; Chalmers, J.J. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. *Biotechnol. Bioeng.* 2009, 102, 521–534. [CrossRef] [PubMed]

69. Balasubramanian, P.; Yang, L.; Lang, J.C.; Jatana, K.R.; Schuller, D.; Agrawal, A.; Zborowski, M.; Chalmers, J.J. Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells. *Mol. Pharm.* 2009, 6, 1402–1408. [CrossRef] [PubMed]

70. Winter, S.C.; Stephenson, S.-A.; Subramaniam, S.K.; Paleri, V.; Ha, K.; Marnane, C.; Krishnan, S.; Rees, G. Long term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma. *BMC Cancer* 2009, 9, 424. [CrossRef] [PubMed]
71. Guney, K.; Yoldas, B.; Ozbilim, G.; Derin, A.T.; Sarihan, S.; Balkan, E. Detection of micrometastatic tumor cells in head and neck squamous cell carcinoma. A possible predictor of recurrences? *Saudi Med. J.* 2007, 28, 216–220. [PubMed]

72. Wollenberg, B.; Walz, A.; Kolbow, K.; Pauli, C.; Chaubal, S.; Andratschke, M. Clinical relevance of circulating tumour cells in the bone marrow of patients with scchn. *Oncol. Res. Treat.* 2004, 27, 358–362. [CrossRef] [PubMed]

73. Wirtschafter, A.; Benninger, M.S.; Moss, T.J.; Umiel, T.; Blazoff, K.; Worsham, M.J. Micrometastatic tumor detection in patients with head and neck cancer: A preliminary report. *Arch. Otolaryngol. Head Neck Surg.* 2002, 128, 40–43. [CrossRef] [PubMed]

74. Dorsey, J.F.; Kao, G.D.; MacArthur, K.M.; Ju, M.; Steinmetz, D.; Wileyto, E.P.; Simone, C.B.; Hahn, S.M. Tracking viable circulating tumor cells (ctcs) in the peripheral blood of non–small cell lung cancer (nsclc) patients undergoing definitive radiation therapy: Pilot study results. *Cancer* 2015, 121, 139–149. [CrossRef] [PubMed]

75. Lowes, L.E.; Lock, M.; Rodrigues, G.; D’Souza, D.; Bauman, G.; Ahmad, B.; Venkatesan, V.; Allan, A.L.; Sexton, T. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. *Clin. Transl. Oncol.* 2012, 14, 150–156. [CrossRef] [PubMed]

76. Jatana, K.R.; Balasubramanian, P.; McMullen, K.P.; Lang, J.C.; Teknos, T.N.; Chalmers, J.J. Effect of surgical intervention on circulating tumor cells in patients with squamous cell carcinoma of the head and neck using a negative enrichment technology. *Head Neck* 2016, 38, 1799–1803. [CrossRef] [PubMed]

77. Jatana, K.R.; Lang, J.C.; Chalmers, J.J. Identification of circulating tumor cells: A prognostic marker in squamous cell carcinoma of the head and neck? *Future Oncol.* 2011, 7, 481–484. [CrossRef] [PubMed]

78. Gao, W.; Li, J.Z.; Ho, W.K.; Chan, J.Y.; Wong, T.S. Biomarkers for use in monitoring responses of nasopharyngeal carcinoma cells to ionizing radiation. *Sensors* 2012, 12, 8832–8846. [CrossRef] [PubMed]

79. Dewey, W.C.; Ling, C.C.; Meyn, R.E. Radiation-induced cell death mechanisms. *Tumour Biol.* 1995, 17, 381–396. [CrossRef] [PubMed]

80. Palumbo, S.; Comincini, S. Autophagy and ionizing radiation in tumors: The “survive or not survive” dilemma. *J. Cell. Physiol.* 2013, 228, 1–8. [CrossRef] [PubMed]

81. Albert, J.M. Radiation risk from ct: Implications for cancer screening. *Am. J. Roentgenol.* 2013, 201, W81–W87. [CrossRef] [PubMed]

82. Rostami, A.; Bratman, S.V. Utilizing circulating tumour DNA in radiation oncology. *Radiother. Oncol.* 2017, 124, 357–364. [CrossRef] [PubMed]

83. Diaz, L.A., Jr.; Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. *J. Clin. Oncol.* 2014, 32, 579–586. [CrossRef] [PubMed]

84. Diehl, F.; Schmidt, K.; Choti, M.A.; Romans, K.; Goodman, S.; Li, M.; Thornton, K.; Agrawal, N.; Sokoll, L.; Szabo, S.A. Circulating mutant DNA to assess metastatic breast cancer. *N. Engl. J. Med.* 2012, 366, 883–892. [CrossRef] [PubMed]

85. Jahr, S.; Hentze, H.; Englisch, S.; Hardt, D.; Fackelmayer, F.O.; Hesch, R.-D.; Knippers, R. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. *Cancer Res.* 2001, 61, 1659–1665. [PubMed]

86. Schwarzenbach, H.; Hoon, D.S.; Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat. Rev. Cancer* 2011, 11, 426. [CrossRef] [PubMed]
91. Wimberger, P.; Roth, C.; Pantel, K.; Kasimir-Bauer, S.; Kimmig, R.; Schwarzenbach, H. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. *Int. J. Cancer* 2011, 128, 2572–2580. [CrossRef] [PubMed]

92. Holdenrieder, S.; Nagel, D.; Schalhorn, A.; Heinemann, V.; Wilkowski, R.; Von Pawel, J.; Raith, H.; Feldmann, K.; Kremer, A.E.; Müller, S. Clinical relevance of circulating nucleosomes in cancer. *Ann. N. Y. Acad. Sci.* 2008, 1137, 180–189. [CrossRef] [PubMed]

93. Lo, Y.D.; Chan, A.T.; Chan, L.Y.; Leung, S.-F.; Lam, C.-W.; Huang, D.P.; Johnson, P. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-barr virus DNA. *Cancer Res.* 2000, 60, 6878–6881. [PubMed]

94. Yu, K.H.; Lo, Y.D.; Gary, M.T.; Chan, K.A.; Chan, A.B.; Chow, K.C.; Ma, T.K.; Vlantis, A.C.; Leung, S.F.; van Hasselt, C.A. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas. *Clin. Cancer Res.* 2004, 10, 1726–1732. [CrossRef] [PubMed]

95. Chan, A.T.; Lo, Y.D.; Zee, B.; Chan, L.Y.; Ma, B.B.; Leung, S.-F.; Mo, F.; Lai, M.; Ho, S.; Huang, D.P. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. *J. Natl. Cancer Inst.* 2002, 94, 1614–1619. [CrossRef] [PubMed]

96. Leung, S.-F.; Zee, B.; Ma, B.B.; Hui, E.P.; Mo, F.; Lai, M.; Chan, K.A.; Chan, L.Y.; Kwan, W.-H.; Lo, Y.D. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. *J. Clin. Oncol.* 2006, 24, 5414–5418. [CrossRef] [PubMed]

97. Lin, J.-C.; Wang, W.-Y.; Chen, K.Y.; Wei, Y.-H.; Liang, W.-M.; Jan, J.-S.; Jiang, R.S. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. *N. Engl. J. Med.* 2004, 350, 2461–2470. [CrossRef] [PubMed]

98. Lo, Y.D.; Chan, L.Y.; Lo, K.-W.; Leung, S.-F.; Zhang, J.; Chan, A.T.; Lee, J.C.; Hjelm, N.M.; Johnson, P.J.; Huang, D.P. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. *Cancer Res.* 1999, 59, 1188–1191. [PubMed]

99. Lo, Y.; Leung, S.; Chan, L.; Lo, K.; Zhang, J.; Chan, A.; Lee, J.; Hjelm, N.; Johnson, P.; Huang, D. Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma: Correlation with clinical staging. *Ann. N. Y. Acad. Sci.* 2000, 906, 99–101. [CrossRef] [PubMed]

100. Wang, W.Y.; Twu, C.W.; Chen, H.H.; Jiang, R.S.; Wu, C.T.; Liang, K.L.; Shih, Y.T.; Chen, C.C.; Lin, P.J.; Liu, Y.C. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. *Cancer* 2013, 119, 963–970. [CrossRef] [PubMed]

101. Chaudhuri, A.; Binkley, M.S.; Osmundson, E.C.; Alizadeh, A.A.; Diehn, M. Predicting Radiotherapy Responses and Treatment Outcomes through Analysis of Circulating Tumor DNA; Elsevier: Amsterdam, The Netherlands, 2015; pp. 305–312.

102. Openshaw, M.R.; Richards, C.J.; Gutterly, D.S.; Shaw, J.A.; Thomas, A.L. The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. *Expert Rev. Mol. Diagn.* 2017, 17, 459–470. [CrossRef] [PubMed]

103. Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M. Detection of circulating tumor DNA in early-and late-stage human malignantancies. *Sci. Transl. Med.* 2014, 6, ra224. [CrossRef] [PubMed]

104. Newman, A.M.; Bratman, S.V.; Stehr, H.; Lee, L.J.; Liu, C.L.; Diehn, M.; Alizadeh, A.A. Factera: A practical method for the discovery of genomic rearrangements at breakpoint resolution. *Bioinformatics* 2014, 30, 3390–3393. [CrossRef] [PubMed]

105. Newman, A.M.; Bratman, S.V.; To, J.; Wynne, J.F.; Elov, N.C.; Modlin, L.A.; Liu, C.L.; Neal, J.W.; Wakelee, H.A.; Merritt, R.E.; et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nat. Med.* 2014, 20, 548–554. [CrossRef] [PubMed]

106. Sidransky, D. Nucleic acid-based methods for the detection of cancer. *Science* 1997, 278, 1054–1058. [CrossRef] [PubMed]

107. Cao, H.; Banh, A.; Kwok, S.; Shi, X.; Wu, S.; Krakow, T.; Khong, B.; Bavan, B.; Bala, R.; Pinsky, B.A. Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. *Int. J. Radiat. Oncol. Biol. Phys.* 2012, 82, e351–e358. [CrossRef] [PubMed]
108. Ahn, S.M.; Chan, J.Y.; Zhang, Z.; Wang, H.; Khan, Z.; Bishop, J.A.; Westra, W.; Koch, W.M.; Califano, J.A. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. *JAMA Otolaryngol. Head Neck Surg.* 2014, 140, 846–854. [CrossRef] [PubMed]

109. Murlidhar, V.; Reddy, R.M.; Fouladdel, S.; Zhao, L.; Ishikawa, M.K.; Graabauskienė, S.; Zhang, Z.; Lin, J.; Chang, A.C.; Carrott, P.; et al. Poor prognosis indicated by venous circulating tumor cell clusters in early-stage lung cancers. *Cancer Res.* 2017, 77, 5194–5206. [CrossRef] [PubMed]

110. Gkountela, S.; Castro-Giner, F.; Szczepankiewicz, B.M.; Vetter, M.; Landin, J.; Scherrer, R.; Krol, I.; Scheidmann, M.C.; Beisel, C.; Stirmann, C.U.; et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. *Cell* 2019, 176, 98.e114–112.e114. [CrossRef] [PubMed]

111. Murtaza, M.; Dawson, S.-J.; Tsui, D.W.; Gale, D.; Forshew, T.; Piskorz, A.M.; Parkinson, C.; Chin, S.-F.; Kingsbury, Z.; Wong, A.S. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature* 2013, 497, 108. [CrossRef] [PubMed]

112. Twu, C.W.; Wang, W.Y.; Liang, W.M.; Jan, J.S.; Jiang, R.S.; Chao, J.; Jin, Y.T.; Lin, J.C. Comparison of the prognostic impact of serum anti-ebv antibody and plasma ebv DNA assays in nasopharyngeal carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* 2007, 67, 130–137. [CrossRef] [PubMed]

113. Praharaj, P.P.; Bhutia, S.K.; Nagrath, S.; Bitting, R.L.; Deep, G. Circulating tumor cell-derived organoids: Current challenges and promises in clinical and experimental medicine. *Biochim. Biophys. Acta Rev. Cancer* 2018, 1869, 117–127. [CrossRef] [PubMed]

114. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M.; et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. *Science* 2013, 339, 580–584. [CrossRef] [PubMed]

115. Cayrefourcq, L.; Mazard, T.; Joosse, S.; Solassol, J.; Ramos, J.; Assenat, E.; Schumacher, U.; Costes, V.; Murtaza, M.; Dawson, S.-J.; Tsui, D.W.; Gale, D.; Forshew, T.; Piskorz, A.M.; Parkinson, C.; Chin, S.-F.; Kingsbury, Z.; Wong, A.S. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature* 2013, 497, 108. [CrossRef] [PubMed]

116. Hodgkinson, C.L.; Morrow, C.J.; Li, Y.; Metcalf, R.L.; Rothwell, D.G.; Trapani, F.; Polanski, R.; Burt, D.J.; Simpson, K.L.; Morris, K.; et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. *Nat. Med.* 2014, 20, 897–903. [CrossRef] [PubMed]

117. Aceto, N.; Bardia, A.; Miyamoto, D.T.; Donaldson, M.C.; Wittner, B.S.; Spencer, J.A.; Yu, M.; Pely, A.; Engstrom, A.; Zhu, H.; et al. Circulating breast tumor cells clusters are oligoclonal precursors of breast cancer metastasis. *Cell* 2014, 158, 1110–1122. [CrossRef] [PubMed]

118. Long, E.; Ilie, M.; Bence, C.; Butor, C.; Selva, E.; Lalvée, S.; Bonnetaud, C.; Poissonnet, G.; Lacour, J.P.; Bahadoran, P.; et al. High expression of trf2, sox10, and cd10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness. *Cancer Med.* 2015, 4, 176–187. [CrossRef] [PubMed]

119. Bobek, V.; Matkowski, R.; Gurlich, R.; Grabowski, K.; Szelachowska, J.; Lischke, R.; Schutzner, J.; Harustiak, T.; Pazdro, A.; Rzechonek, A.; et al. Cultivation of circulating tumor cells in esophageal cancer. *Folia Histochem. Cytobiol.* 2014, 52, 171–177. [CrossRef] [PubMed]

120. Luo, Y.T.; Cheng, J.; Feng, X.; He, S.J.; Wang, Y.W.; Huang, Q. The viable circulating tumor cells with cancer stem cells feature, where is the way out? *J. Exp. Clin. Cancer Res. CR* 2018, 37, 38. [CrossRef] [PubMed]

121. Moitra, K.; Lou, H.; Dean, M. Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development. *Clin. Pharmacol. Ther.* 2011, 89, 491–502. [CrossRef] [PubMed]

122. Warrier, S.; Bhuvalanalakshmi, G.; Arfuso, F.; Rajan, G.; Millward, M.; Dharmarajan, A. Cancer stem-like cells from head and neck cancers are chemosensitized by the wnt antagonist, sfrp4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. *Cancer Gene Ther.* 2014, 21, 381. [CrossRef] [PubMed]

123. Patel, S.S.; Shah, K.A.; Shah, M.J.; Kothari, K.C.; Rawal, R.M. Cancer stem cells and stemness markers in oral squamous cell carcinomas. *Asian Pac. J. Cancer Prev.* 2014, 15, 8549–8556. [CrossRef] [PubMed]

124. Major, A.G.; Pitty, L.P.; Farah, C.S. Cancer stem cell markers in head and neck squamous cell carcinoma. *Stem Cells Int.* 2013, 2013, 319489. [CrossRef] [PubMed]

125. Vlashi, E.; Chen, A.M.; Boyrie, S.; Yu, G.; Nguyen, A.; Brower, P.A.; Hess, C.B.; Pajonk, F. Radiation-induced dedifferentiation of head and neck cancer cells into cancer stem cells depends on human papillomavirus status. *Int. J. Radiat. Oncol. Biol. Phys.* 2016, 94, 1198–1206. [CrossRef] [PubMed]
Cancers 2019, 11, 367

126. Pretlow, T.G.; Schwartz, S.; Giaconia, J.M.; Wright, A.L.; Grimm, H.A.; Edgehouse, N.L.; Murphy, J.R.; Markowitz, S.D.; Jamison, J.M.; Summers, J.L. Prostate cancer and other xenografts from cells in peripheral blood of patients. Cancer Res. 2000, 60, 4033–4036. [PubMed]

127. Gao, D.; Vela, I.; Sboner, A.; Iaquinta, P.J.; Karthaus, W.R.; Gopalan, A.; Dowling, C.; Wanjala, J.N.; Undvall, E.A.; Arora, V.K. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014, 159, 176–187. [CrossRef] [PubMed]

128. Levina, V.; Marrangoni, A.M.; DeMarco, R.; Gorelik, E.; Lokshin, A.E. Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008, 3, e3077. [CrossRef] [PubMed]

129. Gomez-Casal, R.; Bhattacharya, C.; Ganesh, N.; Bailey, L.; Basse, P.; Gibson, M.; Epperly, M.; Levina, V. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol. Cancer 2013, 12, 94. [CrossRef] [PubMed]

130. Mirza, S.; Vasiya, A.; Vora, H.; Jain, N.; Rawal, R. Curcumin targets circulating cancer stem cells by inhibiting self-renewal efficacy in non-small cell lung carcinoma. Anti Cancer Agents Med. Chem. 2017, 17, 859–864. [CrossRef] [PubMed]

131. Zhang, S.; Shang, Y.; Chen, T.; Zhou, X.; Meng, W.; Fan, C.; Lu, R.; Huang, Q.; Li, X.; Hong, X. Human circulating and tissue gastric cancer stem cells display distinct epithelial–mesenchymal features and behaviors. J. Cancer Res. Clin. Oncol. 2017, 143, 1687–1699. [CrossRef] [PubMed]

132. Chen, T.; Yang, K.; Yu, J.; Meng, W.; Yuan, D.; Bi, F.; Liu, F.; Liu, J.; Dai, B.; Chen, X. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res. 2012, 22, 248. [CrossRef] [PubMed]

133. Sayed, M.; Zahran, A.; Hassan, M.; Mohamed, D. Circulating tumor cells and cancer stem cells: Clinical implications in nonmetastatic breast cancer. Breast Cancer Basic Clin. Res. 2016, 10, 197. [CrossRef]

134. Katoh, S.; Goti, T.; Naruse, T.; Ueda, Y.; Kurebayashi, H.; Nakazawa, T.; Kimura, Y.; Hirono, Y.; Yamaguchi, A. Cancer stem cell marker in circulating tumor cells: Expression of cd44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer. Anticancer Res. 2015, 35, 239–244. [PubMed]

135. Crea, F.; Fornaro, L.; Masi, G.; Falcone, A.; Danesi, R.; Farrar, W. Faithful markers of circulating cancer stem cells: Is cd133 sufficient for validation in clinics? J. Clin. Oncol. 2011, 29, 3487–3488. [CrossRef] [PubMed]

136. Inimina, H.; Watanabe, T.; Mimori, K.; Adachi, M.; Hayashi, N.; Tamura, J.; Matsuda, K.; Fukushima, R.; Okinaga, K.; Sasako, M. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with dukes’ stage b and c colorectal cancer. J. Clin. Oncol. 2011, 29, 1547–1555. [CrossRef] [PubMed]

137. Kantara, C.; O’Connell, M.; Luthra, G.; Gajjar, A.; Sarkar, S.; Ullrich, R.; Singh, P. Methods for detecting circulating cancer stem cells (ccscs) as a novel approach for diagnosis of colon cancer relapse/metastasis. Lab. Investig. 2015, 95, 100. [CrossRef] [PubMed]

138. Grillot, F.; Bayet, E.; Villeron, O.; Zappia, L.; Lagerqvist, E.L.; Lunke, S.; Charafe-Jauffret, E.; Pham, K.; Molck, C.; Rolland, N.; et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut 2017, 66, 1802–1810. [CrossRef] [PubMed]

139. Khoo, B.L.; Grenci, G.; Lim, J.S.Y.; Lim, Y.P.; Fong, J.; Yeap, W.H.; Bin Lim, S.; Chua, S.L.; Wong, S.C.; Yap, Y.S.; et al. Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. Br. J. Cancer 2019, 120, 407–423. [CrossRef] [PubMed]

140. Chisholm, E.; Bapat, U.; Chisholm, C.; Alusi, G.; Vassaux, G. Gene therapy in head and neck cancer: A review. Postgrad. Med. J. 2007, 83, 731–737. [CrossRef] [PubMed]

141. Fda approves second car t-cell therapy. Cancer Discov. 2018, 8, 5–6. [CrossRef] [PubMed]

142. Kloss, C.C.; Lee, J.; Zhang, A.; Chen, F.; Melenhorst, J.J.; Lacey, S.F.; Maus, M.V.; Fraietta, J.A.; Zhao, Y.; June, C.H. Dominant-negative tgf-beta receptor enhances psma-targeted human car t cell proliferation and augments prostate cancer eradication. Mol. Ther. 2018, 26, 1855–1866. [CrossRef] [PubMed]

143. Newick, K.; O’Brien, S.; Moon, E.; Albelda, S.M. Car t cell therapy for solid tumors. Annu. Rev. Med. 2017, 68, 139–152. [CrossRef] [PubMed]
144. Teh, B.S.; Aguilar-Cordova, E.; Vlachaki, M.T.; Aguilar, L.; Mai, W.Y.; Caillouet, J.; Davis, M.; Miles, B.; Kadmon, D.; Ayala, G.; et al. Combining radiotherapy with gene therapy (from the bench to the bedside): A novel treatment strategy for prostate cancer. Oncologist 2002, 7, 458–466. [CrossRef] [PubMed]

145. Bristow, R.G.; Alexander, B.; Baumann, M.; Bratman, S.V.; Brown, J.M.; Camphausen, K.; Choyke, P.; Citrin, D.; Contessa, J.N.; Dicker, A.; et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: A guideline by the american society for radiation oncology. Lancet Oncol. 2018, 19, e240–e251. [CrossRef] [PubMed]

146. Pramana, J.; Van den Brekel, M.W.; van Velthuysen, M.L.; Wessels, L.F.; Nuyten, D.S.; Hofland, I.; Atsma, D.; Pimentel, N.; Hoebers, F.J.; Rasch, C.R.; et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69, 1544–1552. [CrossRef] [PubMed]

147. Torres-Roca, J.F.; Eschrich, S.; Zhao, H.; Bloom, G.; Sung, J.; McCarthy, S.; Cantor, A.B.; Scuto, A.; Li, C.; Zhang, S.; et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 2005, 65, 7169–7176. [CrossRef] [PubMed]

148. Ma, B.B.; Bristow, R.G.; Kim, J.; Siu, L.L. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J. Clin. Oncol. 2003, 21, 2760–2776. [CrossRef] [PubMed]

149. Marples, B.; Collis, S.J. Low-dose hyper-radiosensitivity: Past, present, and future. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 1310–1318. [CrossRef] [PubMed]

150. Lindsay, K.; Coates, P.; Lorimore, S.; Wright, E. The genetic basis of tissue responses to ionizing radiation. Br. J. Radiol. 2007, 80, S2–S6. [CrossRef]

151. Eschrich, S.A.; Pramana, J.; Zhang, H.; Zhao, H.; Boulware, D.; Lee, J.-H.; Bloom, G.; Rocha-Lima, C.; Kelley, S.; Calvin, D.P. A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75, 489–496. [CrossRef] [PubMed]

152. Scott, J.G.; Berglund, A.; Schell, M.J.; Mihaylov, I.; Fulp, W.J.; Yue, B.; Welsh, E.; Caudell, J.J.; Ahmed, K.; Strom, T.S. A genome-based model for adjusting radiotherapy dose (gard): A retrospective, cohort-based study. Lancet Oncol. 2017, 18, 202–211. [CrossRef] [PubMed]

153. Braunholz, D.; Saki, M.; Niehr, F.; Ozturk, M.; Borras Puertolas, B.; Konschak, R.; Budach, V.; Tinhofer, I. Spheroid culture of head and neck cancer cells reveals an important role of egfr signalling in anchorage independent survival. PloS ONE 2016, 11, e0163149. [CrossRef] [PubMed]

154. Maheswaran, S.; Sequist, L.V.; Nagaroth, S.; Ulkus, L.; Brannigan, B.; Collura, C.V.; Inserra, E.; Diederichs, S.; Iafrate, A.J.; Bell, D.W. Detection of mutations in egfr in circulating lung-cancer cells. N. Engl. J. Med. 2008, 359, 366–377. [CrossRef] [PubMed]

155. Egloff, A.M.; Grandis, J.R. Targeting Epidermal Growth Factor Receptor and Src Pathways in Head and Neck Cancer; Elsevier: Amsterdam, The Netherlands, 2008; pp. 286–297.

156. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567–578. [CrossRef] [PubMed]

157. Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.-R.; Cupissol, D. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359, 1116–1127. [CrossRef] [PubMed]

158. Tinhofer, I.; Hristozova, T.; Stromberger, C.; Keilholz, U.; Budach, V. Monitoring of circulating tumor cells and their expression of egfr/phospho-egfr during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 2012, 83, e685–e690. [CrossRef] [PubMed]

159. Gemmill, J. Cetuximab: A critical appraisal of a novel development in the treatment of squamous cell carcinoma of the head and neck. J. Radiother. Pract. 2008, 7, 1–7. [CrossRef]

160. Wagner, T.D.; Yang, G.Y. Cetuximab: Its use in combination with radiation therapy and chemotherapy in the multimodality treatment of head and neck cancer. Recent Pat. Anti Cancer Drug Discov. 2008, 3, 76–83. [CrossRef]

161. Mcbride, W.H.; Dougherty, G.J. Radiotherapy for genes that cause cancer. Nat. Med. 1995, 1, 1215–1217. [CrossRef] [PubMed]
162. Chougule, P.B.; Suk, S.; Chu, Q.D.; Leone, L.; Nigri, P.T.; McRae, R.; Lekas, M.; Barone, A.; Bhat, D.; Bellino, J. Cisplatin as a radiation sensitizer in the treatment of advanced head and neck cancers. Results of a phase ii study. *Cancer* 1994, 74, 1927–1932. [CrossRef]

163. Douple, E.B.; Eaton, W.L.; Tulloh, M.E. Skin radiosensitization studies using combined cis-dichlorodiammineplatinum (ii) and radiation. *Int. J. Radiat. Oncol. Biol. Phys.* 1979, 5, 1383–1385. [CrossRef]

164. Leipzig, B.; Wetmore, S.J.; Putzeys, R.; Suen, J.Y.; Snyderman, N.L. Cisplatin potentiation of radiotherapy: Long-term follow-up. *Arch. Otolaryngol.* 1985, 111, 114–118. [CrossRef] [PubMed]

165. Al-Sarraf, M.; Pajak, T.F.; Marcial, V.A.; Mowry, P.; Cooper, J.S.; Stetz, J.; Ensley, J.F.; Velez-Garcia, E. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An rtog study. *Cancer* 1987, 59, 259–265. [CrossRef]

166. Marcial, V.A.; Pajak, T.F.; Mohiuddin, M.; Cooper, J.S.; Al Sarraf, M.; Mowry, P.A.; Curran, W.; Crissman, J.; Rodriguez, M.; Velez-Garca, E. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the radiation therapy oncology group study 81-17. *Cancer* 1990, 66, 1861–1868. [CrossRef]

167. Taylor, S.; Murthy, A.; Showel, J.; Caldarelli, D.; Hutchinson, J., Jr.; Holinger, L.; Kramer, T.; Kiel, K. Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-fu chemotherapy. *Cancer Treat. Rep.* 1985, 69, 933–939. [PubMed]

168. Leipzig, B. Cisplatin sensitization to radiotherapy of squamous cell carcinomas of the head and neck. *Am. J. Surg.* 1983, 146, 462–465. [CrossRef]

169. Ang, K.K.; Zhang, Q.; Rosenthal, D.I.; Nguyen-Tan, P.F.; Sherman, E.J.; Weber, R.S.; Galvin, J.M.; Bonner, J.A.; Harris, J.; El-Naggar, A.K. Randomized phase iii trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage iii to iv head and neck carcinoma: Rtog 0522. *J. Clin. Oncol.* 2014, 32, 2940–2950. [CrossRef] [PubMed]

170. Rischin, D.; Peters, L.J.; O’Sullivan, B.; Giralt, J.; Fisher, R.; Yuen, K.; Trotti, A.; Bernier, J.; Ringash, J. Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-fu chemotherapy. *Cancer* 1990, 66, 1861–1868. [CrossRef]

171. Overgaard, J.; Hansen, H.S.; Overgaard, M.; Bastholt, L.; Berthelsen, A.; Specht, L.; Lindeløv, B.; Jørgensen, K. A randomized double-blind phase iii study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the danish head and neck cancer study (dahanca) protocol 5-85. *Radiother. Oncol.* 1998, 46, 135–146. [CrossRef] [PubMed]

172. Miyamoto, D.T.; Zheng, Y.; Wittner, B.S.; Lee, R.J.; Zhu, H.; Broderick, K.T.; Desai, R.; Fox, D.B.; Brannigan, B.W.; Trautzwein, J. Rna-seq of single prostate ctc implicates noncanonical wnt signaling in antiandrogen resistance. *Science* 2015, 349, 1351–1356. [CrossRef] [PubMed]

173. Yu, M.; Ting, D.T.; Stott, S.L.; Wittner, B.S.; Oszolak, F.; Paul, S.; Cecilian, J.C.; Smas, M.E.; Winokur, D.; Gilman, A.J. Rna sequencing of pancreatic circulating tumour cells implicates wnt signaling in metastasis. *Nature* 2012, 487, 510. [CrossRef] [PubMed]

174. Sidaway, P. Prostate cancer: Wnt signalling induces resistance. *Nat. Rev. Urol.* 2015, 12, 597. [CrossRef] [PubMed]

175. Bhuvanalakshmi, G.; Arfuso, F.; Millward, M.; Dharmarajan, A.; Warrier, S. Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties. *PLoS ONE* 2015, 10, e0127517.

176. Constantinou, T.; Baumann, F.; Lacher, M.D.; Saurer, S.; Friis, R.; Dharmarajan, A. Sfrp-4 abrogates wnt-3a-induced β-catenin and akt/pkb signalling and reverses a wnt-3a-imposed inhibition of in vitro mammary differentiation. *J. Mol. Signal.* 2008, 3, 10. [CrossRef] [PubMed]

177. Deshmukh, A.; Kumar, S.; Arfuso, F.; Newsholme, P.; Dharmarajan, A. Secreted frizzled-related protein 4 (sfrp4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines. *Sci. Rep.* 2017, 7, 2256. [CrossRef] [PubMed]

178. Drake, J.M.; Friis, R.R.; Dharmarajan, A.M. The role of sfrp4, a secreted frizzled-related protein, in ovulation. *Apoptosis* 2003, 8, 389–397. [CrossRef] [PubMed]
179. Fox, S.A.; Richards, A.K.; Kusumah, I.; Perumal, V.; Bolitho, E.M.; Mutsaers, S.E.; Dharmarajan, A.M. Expression profile and function of wnt signaling mechanisms in malignant mesothelioma cells. *Biochem. Biophys. Res. Commun.* 2013, 440, 82–87. [CrossRef] [PubMed]

180. Hsieh, M.; Mulders, S.M.; Friis, R.R.; Dharmarajan, A.; Richards, J.S. Expression and localization of secreted frizzled-related protein 4 in the rodent ovary: Evidence for selective up-regulation in luteinized granulosa cells. *Endocrinology* 2003, 144, 4597–4606. [CrossRef] [PubMed]

181. Longman, D.; Arfuso, F.; Viola, H.M.; Hool, L.C.; Dharmarajan, A.M. The role of the cysteine-rich domain and netrin-like domain of secreted frizzled-related protein 4 in angiogenesis inhibition in vitro. *Oncol. Res.Feat. Preclin. Clin. Cancer Ther.* 2012, 20, 1–6. [CrossRef]

182. Muley, A.; Majumder, S.; Kolluru, G.K.; Parkinson, S.; Viola, H.; Hool, L.; Arfuso, F.; Ganss, R.; Dharmarajan, A.; Chatterjee, S. Secreted frizzled-related protein 4: An angiogenesis inhibitor. *Am. J. Pathol.* 2010, 176, 1505–1516. [CrossRef] [PubMed]

183. Perumal, V.; Dharmarajan, A.M.; Fox, S.A. The wnt regulator sfrp4 inhibits mesothelioma cell proliferation, migration, and antagonizes wnt3a via its netrin-like domain. *Int. J. Oncol.* 2017, 51, 362–368. [CrossRef] [PubMed]

184. Perumal, V.; Krishnan, K.; Gratton, E.; Dharmarajan, A.M.; Fox, S.A. Number and brightness analysis of sfrp4 domains in live cells demonstrates vesicle association signal of the nld domain and dynamic intracellular responses to wnt3a. *Int. J. Biochem. Cell Biol.* 2015, 64, 91–96. [CrossRef] [PubMed]

185. Perumal, V.; Pohl, S.; Keane, K.N.; Arfuso, F.; Newsholme, P.; Fox, S.; Dharmarajan, A. Therapeutic approach to target mesothelioma cancer cells using the wnt antagonist, secreted frizzled-related protein 4: Metabolic state of cancer cells. *Exp. Cell Res.* 2016, 341, 218–224. [CrossRef] [PubMed]

186. Warrier, S.; Balu, S.K.; Kumar, A.P.; Millward, M.; Dharmarajan, A. Wnt antagonist, secreted frizzled-related protein 4 (sfrp4), increases chemotherapeutic response of glioma stem-like cells. *Oncol. Res. Featur. Preclin. Clin. Cancer Ther.* 2014, 21, 93–102. [CrossRef] [PubMed]

187. Perumal, V.; Arfuso, F.; Chen, Y.; Fox, S.; Dharmarajan, A.M. Delivery of expression constructs of secreted frizzled-related protein 4 and its domains by chitosan-dextran sulfate nanoparticles enhances their expression and anti-cancer effects. *Mol. Cell. Biochem.* 2018, 443, 205–213. [CrossRef] [PubMed]

188. Jun, S.; Jung, Y.S.; Suh, H.N.; Wang, W.; Kim, M.J.; Oh, Y.S.; Lien, E.M.; Shen, X.; Matsumoto, Y.; McCrea, P.D. Lg4 mediates wnt signalling-induced radioresistance. *Nat. Commun.* 2016, 7, 10994. [CrossRef] [PubMed]

189. Ravindran, G.; Sawant, S.S.; Hague, A.; Kingsley, K.; Devaraj, H. Association of differential β-catenin expression with oct-4 and nanog in oral squamous cell carcinoma and their correlation with clinicopathological factors and prognosis. *Head Neck* 2015, 37, 982–993. [CrossRef] [PubMed]

190. Padhi, S.; Saha, A.; Kar, M.; Ghosh, C.; Adhya, A.; Baisakh, M.; Mohapatra, N.; Venkatesan, S.; Hande, M.P.; Banerjee, B. Clinico-pathological correlation of β-catenin and telomere dysfunction in head and neck squamous cell carcinoma patients. *J. Cancer* 2015, 6, 192. [CrossRef] [PubMed]

191. Dong, Z.; Zhou, L.; Han, N.; Zhang, M.; Lyu, X. Wnt/β-catenin pathway involvement in ionizing radiation-induced invasion of u87 glioblastoma cells. *Strahlenther. Onkol.* 2015, 191, 672–680. [CrossRef] [PubMed]

192. Armstrong, A.J.; Marengo, M.S.; Oltean, S.; Kemeny, G.; Biting, R.; Turnbull, J.; Herold, C.I.; Marcom, P.K.; George, D.; Garcia-Blanco, M. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. *Mol. Cancer Res.* 2011, 9, 997–1007. [CrossRef] [PubMed]

193. Ysebaert, L.; Chicanne, G.; Demur, C.; De Toni, F.; Prade-Houdellier, N.; Ruidavets, J.; Mansat-De Mas, V.; Rigalet-Huguet, F.; Laurent, G.; Payrastre, B. Expression of [beta]-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. *Leukemia* 2006, 20, 1211. [CrossRef] [PubMed]

194. Vermeulen, L.; Todaro, M.; de Sousa Mello, F.; Sprick, M.R.; Kemper, K.; Alea, M.P.; Richel, D.J.; Stassi, G.; Medema, J.P. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. *Proc. Natl. Acad. Sci. USA* 2008, 105, 13427–13432. [CrossRef] [PubMed]

195. Von Rahden, B.H.; Kircher, S.; Lazariotou, M.; Reiber, C.; Stuermer, L.; Otto, C.; Germer, C.T.; Grimm, M. Lgr5 expression and cancer stem cell hypothesis: Clue to define the true origin of esophageal adenocarcinomas with and without barrett’s esophagus? *J. Exp. Clin. Cancer Res.* CR 2011, 30, 23. [CrossRef] [PubMed]

196. Rothenberger, N.J.; Stabile, L.P. Hepatocyte growth factor/c-met signaling in head and neck cancer and implications for treatment. *Cancers* 2017, 9, 39. [CrossRef] [PubMed]
197. Sun, S.; Liu, S.; Duan, S.Z.; Zhang, L.; Zhou, H.; Hu, Y.; Zhou, X.; Shi, C.; Zhou, R.; Zhang, Z. Targeting the c-met/fzd8 signaling axis eliminates patient-derived cancer stem–like cells in head and neck squamous carcinomas. *Cancer Res.* **2014**, *74*, 7546–7559. [CrossRef] [PubMed]

198. Zhang, T.; Boominathan, R.; Foulk, B.; Rao, C.; Kemeny, G.; Strickler, J.H.; Abbruzzese, J.L.; Harrison, M.R.; Hsu, D.S.; Healy, P. Development of a novel c-met–based ctc detection platform. *Mol. Cancer Res.* **2016**, *14*, 539–547. [CrossRef] [PubMed]

199. Zou, H.Y.; Li, Q.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.J.; Kung, P.P.; et al. An orally available small-molecule inhibitor of c-met, pf-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. *Cancer Res.* **2007**, *67*, 4408–4417. [CrossRef] [PubMed]

200. Schmitz, S.; Ang, K.K.; Vermorken, J.; Haddad, R.; Suarez, C.; Wolf, G.T.; Hamoir, M.; Machiels, J.-P. Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions. *Cancer Treat. Rev.* **2014**, *40*, 390–404. [CrossRef] [PubMed]

201. Szturz, P.; Raymond, E.; Faivre, S. C-met-mediated resistance to egfr inhibitors in head and neck cancer: How to move from bench to bedside. *Oral Oncol.* **2016**, *59*, e12. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).